Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

Chintamani Atreya, Simone Glynn, Michael Busch, Steve Kleinman, Edward Snyder, Sara Rutter, James AuBuchon, Willy Flegel, David Reeve, Dana Divine, Claudia Cohn, Brian Custer, Raymond Goodrich, Richard J. Benjamin, Anna Razatos, Jose Cancelas, Stephen Wagner, Michelle MacLean, Monique Gelderman, Andrew Cap & 1 others Paul Ness

Research output: Contribution to journalConference Contribution

2 Citations (Scopus)

Abstract

On November 29, 2018, experts in the field of infectious diseases, pathogen reduction technologies (PRTs) and other participants from blood centers, academia, and industry gathered at the Food and Drug Administration (FDA) White Oak Campus in Silver Spring, Maryland, for a 2‐day public workshop entitled “Pathogen Reduction Technologies for Blood Safety.” The workshop opened with welcome remarks from Dr. Nicole Verdun, Director, Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), FDA, followed by introductory remarks from Dr. Peter Marks, Director, CBER, FDA. The first day of the workshop focused on blood‐borne infectious agents and their impact on blood safety, experiences of the American Red Cross, and other blood establishments in implementing FDA‐approved pathogen inactivation (PI) technology for plasma and platelets (PLTs) in the United States and novel PRTs under consideration for whole blood (WB) and red blood cells (RBCs).

The second day opened with welcome remarks from Dr. Chintamani Atreya, Associate Director for Research, OBRR, CBER, FDA. The focus was on emerging innovations relevant to PRTs and potential alternatives to PRTs. The workshop concluded with remarks on insights for future research and development in this area for blood and blood product safety from infectious agents.

A brief introduction of each session by the session moderator followed by a summary of the speaker presentation as submitted by the moderator and speaker are reported here.
LanguageEnglish
Pages3002-3025
Number of pages24
JournalTransfusion
Volume59
Issue number9
Early online date29 May 2019
DOIs
Publication statusPublished - 30 Sep 2019

Fingerprint

Blood Safety
United States Food and Drug Administration
Technology
Education
Biological Products
Research
Red Cross
Silver
Communicable Diseases
Industry
Blood Platelets
Erythrocytes

Keywords

  • pathogen reduction technologies (PRTs)
  • infectious diseases
  • blood-borne infectious agents
  • blood safety
  • pathogen inactivation
  • plasma and platelets

Cite this

Atreya, Chintamani ; Glynn, Simone ; Busch, Michael ; Kleinman, Steve ; Snyder, Edward ; Rutter, Sara ; AuBuchon, James ; Flegel, Willy ; Reeve, David ; Divine, Dana ; Cohn, Claudia ; Custer, Brian ; Goodrich, Raymond ; Benjamin, Richard J. ; Razatos, Anna ; Cancelas, Jose ; Wagner, Stephen ; MacLean, Michelle ; Gelderman, Monique ; Cap, Andrew ; Ness, Paul. / Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026). 2019 ; Vol. 59, No. 9. pp. 3002-3025.
@article{80a00289741f48978ee1d4cc4cf18103,
title = "Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)",
abstract = "On November 29, 2018, experts in the field of infectious diseases, pathogen reduction technologies (PRTs) and other participants from blood centers, academia, and industry gathered at the Food and Drug Administration (FDA) White Oak Campus in Silver Spring, Maryland, for a 2‐day public workshop entitled “Pathogen Reduction Technologies for Blood Safety.” The workshop opened with welcome remarks from Dr. Nicole Verdun, Director, Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), FDA, followed by introductory remarks from Dr. Peter Marks, Director, CBER, FDA. The first day of the workshop focused on blood‐borne infectious agents and their impact on blood safety, experiences of the American Red Cross, and other blood establishments in implementing FDA‐approved pathogen inactivation (PI) technology for plasma and platelets (PLTs) in the United States and novel PRTs under consideration for whole blood (WB) and red blood cells (RBCs).The second day opened with welcome remarks from Dr. Chintamani Atreya, Associate Director for Research, OBRR, CBER, FDA. The focus was on emerging innovations relevant to PRTs and potential alternatives to PRTs. The workshop concluded with remarks on insights for future research and development in this area for blood and blood product safety from infectious agents.A brief introduction of each session by the session moderator followed by a summary of the speaker presentation as submitted by the moderator and speaker are reported here.",
keywords = "pathogen reduction technologies (PRTs), infectious diseases, blood-borne infectious agents, blood safety, pathogen inactivation, plasma and platelets",
author = "Chintamani Atreya and Simone Glynn and Michael Busch and Steve Kleinman and Edward Snyder and Sara Rutter and James AuBuchon and Willy Flegel and David Reeve and Dana Divine and Claudia Cohn and Brian Custer and Raymond Goodrich and Benjamin, {Richard J.} and Anna Razatos and Jose Cancelas and Stephen Wagner and Michelle MacLean and Monique Gelderman and Andrew Cap and Paul Ness",
year = "2019",
month = "9",
day = "30",
doi = "10.1111/trf.15344",
language = "English",
volume = "59",
pages = "3002--3025",
number = "9",

}

Atreya, C, Glynn, S, Busch, M, Kleinman, S, Snyder, E, Rutter, S, AuBuchon, J, Flegel, W, Reeve, D, Divine, D, Cohn, C, Custer, B, Goodrich, R, Benjamin, RJ, Razatos, A, Cancelas, J, Wagner, S, MacLean, M, Gelderman, M, Cap, A & Ness, P 2019, 'Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)' vol. 59, no. 9, pp. 3002-3025. https://doi.org/10.1111/trf.15344

Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026). / Atreya, Chintamani; Glynn, Simone; Busch, Michael; Kleinman, Steve; Snyder, Edward; Rutter, Sara; AuBuchon, James; Flegel, Willy; Reeve, David; Divine, Dana; Cohn, Claudia; Custer, Brian; Goodrich, Raymond; Benjamin, Richard J.; Razatos, Anna; Cancelas, Jose; Wagner, Stephen; MacLean, Michelle; Gelderman, Monique; Cap, Andrew; Ness, Paul.

Vol. 59, No. 9, 30.09.2019, p. 3002-3025.

Research output: Contribution to journalConference Contribution

TY - JOUR

T1 - Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

AU - Atreya, Chintamani

AU - Glynn, Simone

AU - Busch, Michael

AU - Kleinman, Steve

AU - Snyder, Edward

AU - Rutter, Sara

AU - AuBuchon, James

AU - Flegel, Willy

AU - Reeve, David

AU - Divine, Dana

AU - Cohn, Claudia

AU - Custer, Brian

AU - Goodrich, Raymond

AU - Benjamin, Richard J.

AU - Razatos, Anna

AU - Cancelas, Jose

AU - Wagner, Stephen

AU - MacLean, Michelle

AU - Gelderman, Monique

AU - Cap, Andrew

AU - Ness, Paul

PY - 2019/9/30

Y1 - 2019/9/30

N2 - On November 29, 2018, experts in the field of infectious diseases, pathogen reduction technologies (PRTs) and other participants from blood centers, academia, and industry gathered at the Food and Drug Administration (FDA) White Oak Campus in Silver Spring, Maryland, for a 2‐day public workshop entitled “Pathogen Reduction Technologies for Blood Safety.” The workshop opened with welcome remarks from Dr. Nicole Verdun, Director, Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), FDA, followed by introductory remarks from Dr. Peter Marks, Director, CBER, FDA. The first day of the workshop focused on blood‐borne infectious agents and their impact on blood safety, experiences of the American Red Cross, and other blood establishments in implementing FDA‐approved pathogen inactivation (PI) technology for plasma and platelets (PLTs) in the United States and novel PRTs under consideration for whole blood (WB) and red blood cells (RBCs).The second day opened with welcome remarks from Dr. Chintamani Atreya, Associate Director for Research, OBRR, CBER, FDA. The focus was on emerging innovations relevant to PRTs and potential alternatives to PRTs. The workshop concluded with remarks on insights for future research and development in this area for blood and blood product safety from infectious agents.A brief introduction of each session by the session moderator followed by a summary of the speaker presentation as submitted by the moderator and speaker are reported here.

AB - On November 29, 2018, experts in the field of infectious diseases, pathogen reduction technologies (PRTs) and other participants from blood centers, academia, and industry gathered at the Food and Drug Administration (FDA) White Oak Campus in Silver Spring, Maryland, for a 2‐day public workshop entitled “Pathogen Reduction Technologies for Blood Safety.” The workshop opened with welcome remarks from Dr. Nicole Verdun, Director, Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), FDA, followed by introductory remarks from Dr. Peter Marks, Director, CBER, FDA. The first day of the workshop focused on blood‐borne infectious agents and their impact on blood safety, experiences of the American Red Cross, and other blood establishments in implementing FDA‐approved pathogen inactivation (PI) technology for plasma and platelets (PLTs) in the United States and novel PRTs under consideration for whole blood (WB) and red blood cells (RBCs).The second day opened with welcome remarks from Dr. Chintamani Atreya, Associate Director for Research, OBRR, CBER, FDA. The focus was on emerging innovations relevant to PRTs and potential alternatives to PRTs. The workshop concluded with remarks on insights for future research and development in this area for blood and blood product safety from infectious agents.A brief introduction of each session by the session moderator followed by a summary of the speaker presentation as submitted by the moderator and speaker are reported here.

KW - pathogen reduction technologies (PRTs)

KW - infectious diseases

KW - blood-borne infectious agents

KW - blood safety

KW - pathogen inactivation

KW - plasma and platelets

UR - https://onlinelibrary.wiley.com/journal/15372995

U2 - 10.1111/trf.15344

DO - 10.1111/trf.15344

M3 - Conference Contribution

VL - 59

SP - 3002

EP - 3025

IS - 9

ER -